Department of Gastrointestinal Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Ann Surg Oncol. 2022 Apr;29(4):2348-2358. doi: 10.1245/s10434-021-11084-w. Epub 2021 Nov 19.
Sarcopenia and cachexia are two predictors of adverse clinical outcomes, but they are partly overlapping. We aimed to compare the characteristics and prognostic value of cachexia and sarcopenia in patients after gastrectomy.
From 2014 to 2019, a total of 1215 gastric cancer patients were enrolled. Cachexia and sarcopenia were diagnosed according to the most recent consensus definitions. Baseline characteristics and clinical outcomes were compared between the two groups. Risk factors of survival were evaluated by Cox regression analysis.
Of all patients, 26.5% were diagnosed with cachexia and 19.8% were diagnosed with sarcopenia. Sarcopenia was more prevalent in elderly patients, while cachexia was prone to occur in patients with TMN stage III. Survival curves showed that sarcopenia had adverse effects in patients with TMN stage I and II-III, while cachexia was only associated with poor survival at stages II-III. For the entire cohort, both cachexia and sarcopenia were adverse factors for prognosis. However, for stage I patients, sarcopenia was an independent predictor for overall survival (OS) (HR = 4.939, P < 0.001) and disease-free survival (DFS) (HR = 4.256, P < 0.001), but not cachexia; for stage II-III patients, cachexia was an independent predictor for OS (HR = 1.538, P < 0.001) and DFS (HR = 1.473, P = 0.001), but not sarcopenia.
Sarcopenia and cachexia have different clinical characteristics and prognostic values. For patients with early stage gastric cancer, detection for sarcopenia was more meaningful than cachexia. However, the prognostic significance of cachexia exceeded sarcopenia in advanced cancer.
肌少症和恶液质是两种不良临床结局的预测因子,但它们部分重叠。本研究旨在比较胃癌术后恶液质和肌少症的特征和预后价值。
本研究纳入了 2014 年至 2019 年间的 1215 名胃癌患者。根据最新的共识定义诊断恶液质和肌少症。比较两组患者的基线特征和临床结局。采用 Cox 回归分析评估生存的危险因素。
所有患者中,26.5%被诊断为恶液质,19.8%被诊断为肌少症。肌少症更常见于老年患者,而恶液质更易发生于 TNM 分期 III 期患者。生存曲线显示,肌少症对 TNM 分期 I 期和 II-III 期患者有不良影响,而恶液质仅与 II-III 期患者的不良预后相关。对于整个队列,恶液质和肌少症均是预后不良的因素。然而,对于 I 期患者,肌少症是总生存(OS)(HR=4.939,P<0.001)和无病生存(DFS)(HR=4.256,P<0.001)的独立预测因子,但恶液质不是;对于 II-III 期患者,恶液质是 OS(HR=1.538,P<0.001)和 DFS(HR=1.473,P=0.001)的独立预测因子,但肌少症不是。
肌少症和恶液质具有不同的临床特征和预后价值。对于早期胃癌患者,检测肌少症比恶液质更有意义。然而,在晚期癌症中,恶液质的预后意义超过了肌少症。